Mirikizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Mirikizumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetinterleukin 23A
Clinical data
SynonymsLY3074828
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6380H9842N1686O2004S48
Molar mass143.8 g/mol g·mol−1

Mirikizumab (LY3074828) (INN[1]) is a human monoclonal antibody designed for the treatment of psoriasis.

This drug was developed by Eli Lilly and Co.[2] As of 2018, mirikizumab is undergoing Phase III trials.

References[edit]

  1. ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Mirikizumab, American Medical Association.